Nature Communications Study by Amelia Haj and Colleagues Identifies Factor XII as a Safer Target for Anticoagulation
Broad Institute of MIT and Harvard shared on LinkedIn:
”Patients diagnosed with life-threatening blood clots known as venous thromboembolisms (VTEs) are treated with anticoagulants, but these drugs increase their risk of bleeding.
In Nature Communications, Amelia Haj, Patrick Ellinor, Pavan Bendapudi, and collaborators make a genetic case for developing therapies targeting coagulation factor XII, a promising and potentially safer antithrombotic drug target.
They used UK Biobank and All of Us data to show that people who have lost one copy of the F12 gene have lower VTE risk without an increased risk of bleeding.
Their study suggests that inhibiting factor XII would likely be a safe and effective approach for anticoagulation.”
Read the full article in Nature Communications.
Article: Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysis
Authors: Amelia K. Haj, David S. Paul, Sean J. Jurgens, Harish Eswaran, Lu-Chen Weng, Justine Ryu, Alfonso Rodriguez Espada, Sharjeel Chaudhry, Louis M. Feingold, Kristen Burke, Satoshi Koyama, Xin Wang, Joyce Francis, Seung Hoan Choi, Nigel Mackman, Wolfgang Bergmeier, Alex Burgin, Joel T. Rämö, Patrick T. Ellinor, Steven P. Grover , Pavan K. Bendapudi
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 4, 2026, 13:53Azusa Nagao: Why Is von Willebrand Disease Still Being Missed in Japan?
-
Jul 4, 2026, 13:32Jim Hoffman: Lupus Treatment Must Balance Disease Control with Long-Term Safety
-
Jul 4, 2026, 13:16Jim Vadolas: New Evidence Linking Iron Dysregulation to Inflammation in Myelodysplastic Syndromes
-
Jul 4, 2026, 12:47Panagiota Tsiatsiou: Tissue Factor Biomarkers Reveal Persistent Procoagulant Activity During Combined Androgen Blockade in Prostate Cancer
-
Jul 4, 2026, 12:45Seema Dawood: Abnormal Nuclear Morphology of Neutrophil
-
Jul 4, 2026, 12:34Omar Adwan: Are You Following Proper Phlebotomy Technique?
-
Jul 4, 2026, 12:24Gabriela Hobbs: Outcomes of MPN Patients with Concurrent Driver Mutations
-
Jul 4, 2026, 12:04Lara Bloom: Building Momentum for Rare Diseases
-
Jul 4, 2026, 11:52Heghine Khachatryan: A Valuable Educational Resource on Inhibitor Development